Ignite Creation Date:
2025-12-24 @ 4:21 PM
Ignite Modification Date:
2025-12-25 @ 2:17 PM
Study NCT ID:
NCT03193866
Status:
COMPLETED
Last Update Posted:
2025-04-20
First Post:
2017-04-20
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
COMparison Between All immunoTherapies for Multiple Sclerosis.
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020529', 'term': 'Multiple Sclerosis, Relapsing-Remitting'}], 'ancestors': [{'id': 'D009103', 'term': 'Multiple Sclerosis'}, {'id': 'D020278', 'term': 'Demyelinating Autoimmune Diseases, CNS'}, {'id': 'D020274', 'term': 'Autoimmune Diseases of the Nervous System'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D003711', 'term': 'Demyelinating Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069283', 'term': 'Rituximab'}, {'id': 'D000069442', 'term': 'Natalizumab'}, {'id': 'D000068876', 'term': 'Fingolimod Hydrochloride'}, {'id': 'D000074323', 'term': 'Alemtuzumab'}, {'id': 'D016899', 'term': 'Interferon-beta'}, {'id': 'D000068717', 'term': 'Glatiramer Acetate'}, {'id': 'D000069462', 'term': 'Dimethyl Fumarate'}], 'ancestors': [{'id': 'D058846', 'term': 'Antibodies, Monoclonal, Murine-Derived'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D013110', 'term': 'Sphingosine'}, {'id': 'D000605', 'term': 'Amino Alcohols'}, {'id': 'D000438', 'term': 'Alcohols'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011409', 'term': 'Propylene Glycols'}, {'id': 'D006018', 'term': 'Glycols'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D007370', 'term': 'Interferon Type I'}, {'id': 'D007372', 'term': 'Interferons'}, {'id': 'D016207', 'term': 'Cytokines'}, {'id': 'D036341', 'term': 'Intercellular Signaling Peptides and Proteins'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D001685', 'term': 'Biological Factors'}, {'id': 'D005650', 'term': 'Fumarates'}, {'id': 'D003998', 'term': 'Dicarboxylic Acids'}, {'id': 'D000144', 'term': 'Acids, Acyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'fredrik.piehl@ki.se', 'phone': '+46-(0)8-517 798 40', 'title': 'Professor Fredrik Piehl', 'organization': 'Karolinska Institutet'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}, 'limitationsAndCaveats': {'description': 'COMBAT was an observational real-world study assessing the outcomes of different DMTs as used according to clinical practice. The assignment of treatments was not under investigator control, there was no randomization and no blinding of treatments. Although differences in patient characteristics at treatment start was accounted for by statistical modelling, the risk of residual confounding should be kept in mind.'}}, 'adverseEventsModule': {'timeFrame': '4 years and 9 months, during prospective data collection between 2017 and 2022', 'description': 'Per regulatory approval by the Swedish Medical Products Agency (MPA), the prospective data collection only included Serious Adverse Reactions (SARs) and Suspected Unexpected Serious Adverse Reactions (SUSARs), including All-Cause Mortality. Other adverse events were not collected (i.e., "0" Total Number of participants at risk). Events were collected from annual safety reports to the MPA, which did not include information on line of therapy. Thus, no stratification on therapy line was done.', 'eventGroups': [{'id': 'EG000', 'title': 'RTX (First or Second Line)', 'description': 'Rituximab, as first line or second line DMT', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 1184, 'otherNumAffected': 0, 'seriousNumAtRisk': 1184, 'deathsNumAffected': 1, 'seriousNumAffected': 43}, {'id': 'EG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 884, 'otherNumAffected': 0, 'seriousNumAtRisk': 884, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 97, 'otherNumAffected': 0, 'seriousNumAtRisk': 97, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'DMF (First or Second Line)', 'description': 'Dimethyl fumarate, as first line or second line DMT', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 870, 'otherNumAffected': 0, 'seriousNumAtRisk': 870, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG004', 'title': 'NTZ (First or Second Line)', 'description': 'Natalizumab, as first line or second line DMT', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 767, 'otherNumAffected': 0, 'seriousNumAtRisk': 767, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG005', 'title': 'FGL (First Line)', 'description': 'Fingolimod, first line DMT', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 384, 'otherNumAffected': 0, 'seriousNumAtRisk': 384, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG006', 'title': 'TFL (First Line)', 'description': 'Teriflunomide, first line DMT', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 138, 'otherNumAffected': 0, 'seriousNumAtRisk': 138, 'deathsNumAffected': 1, 'seriousNumAffected': 3}], 'seriousEvents': [{'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Malignant melanoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Serum sickness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Febrile neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Hepatitis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Cardiac failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Breast cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Lung neoplasma malignant', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Pulmonary sarcoidosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Cerebrovascular accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Hypogammaglobulinaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Haemophilus sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Encephalitis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Cervix carcinoma stage II', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Completed suicide', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Cholecystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Abort spontaneous', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Colitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Abdominal abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Myocarditis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Corona virus infections', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Staphylococcal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Tubulointerstitial nephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': "Crohn's disease", 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Colon cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Lyme disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Large granular lymphocytosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Neuroborreliosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Basal cell carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Follicle centre lymphoma, follicular grade I, II, III', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Prostate cancer metastatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}, {'term': 'Inflammatory bowel disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 1184, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 884, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 97, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 870, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 767, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 384, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 138, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.0'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Confirmed Disease Progression in Patients With Expanded Disability Status Scale (EDSS) <2.5 at Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '20', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '18', 'groupId': 'OG005'}, {'value': '25', 'groupId': 'OG006'}, {'value': '19', 'groupId': 'OG007'}, {'value': '19', 'groupId': 'OG008'}, {'value': '8', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.5', 'ciLowerLimit': '-1.8', 'ciUpperLimit': '4.9', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.2', 'ciLowerLimit': '-6.8', 'ciUpperLimit': '6.5', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.3', 'ciLowerLimit': '-1.7', 'ciUpperLimit': '4.3', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.9', 'ciLowerLimit': '-4.3', 'ciUpperLimit': '2.4', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.7', 'ciLowerLimit': '-1.3', 'ciUpperLimit': '4.6', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.3', 'ciLowerLimit': '-2.7', 'ciUpperLimit': '3.3', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.2', 'ciLowerLimit': '-2.0', 'ciUpperLimit': '4.4', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.0', 'ciLowerLimit': '-3.2', 'ciUpperLimit': '7.1', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '3 years', 'description': 'Proportion of patients with baseline EDSS \\<2.5 progressing to 12 months confirmed EDSS ≥3 among those over 3 years of follow up.\n\nExpanded Disability Status Scale (EDSS) scale range:\n\nMinimum score: 0 (normal neurological examination). Maximum score: 10 (death due to multiple sclerosis) Lower scores indicate better outcomes (less disability). Higher scores indicate worse outcomes (more disability).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'PRIMARY', 'title': 'Confirmed Disease Progression in Patients With EDSS ≥2.5 at Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '50', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '32', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '50', 'groupId': 'OG005'}, {'value': '57', 'groupId': 'OG006'}, {'value': '47', 'groupId': 'OG007'}, {'value': '37', 'groupId': 'OG008'}, {'value': '9', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.7', 'ciLowerLimit': '-7.5', 'ciUpperLimit': '8.8', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.9', 'ciLowerLimit': '-18.5', 'ciUpperLimit': '12.8', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.1', 'ciLowerLimit': '-8.8', 'ciUpperLimit': '8.6', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.5', 'ciLowerLimit': '-8.1', 'ciUpperLimit': '7.2', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.6', 'ciLowerLimit': '-5.7', 'ciUpperLimit': '8.9', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.6', 'ciLowerLimit': '-4.7', 'ciUpperLimit': '8.0', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.9', 'ciLowerLimit': '-6.2', 'ciUpperLimit': '7.9', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.6', 'ciLowerLimit': '-10.8', 'ciUpperLimit': '7.5', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '3 years', 'description': '\\- Proportion of patients with baseline EDSS ≥2.5 experiencing 12 months confirmed EDSS increase of 1 point among those over 3 years of follow up\n\nExpanded Disability Status Scale (EDSS) scale range:\n\nMinimum score: 0 (normal neurological examination). Maximum score: 10 (death due to multiple sclerosis) Lower scores indicate better outcomes (less disability). Higher scores indicate worse outcomes (more disability).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'PRIMARY', 'title': 'Disease-related Impact on Daily Life, Physical', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '16.6', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '16.2', 'groupId': 'OG001'}, {'value': '-4.8', 'spread': '17.7', 'groupId': 'OG002'}, {'value': '-1.2', 'spread': '16.1', 'groupId': 'OG003'}, {'value': '-6.3', 'spread': '18.0', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '14.5', 'groupId': 'OG005'}, {'value': '-0.5', 'spread': '13.3', 'groupId': 'OG006'}, {'value': '-2.1', 'spread': '16.4', 'groupId': 'OG007'}, {'value': '-1.3', 'spread': '14.3', 'groupId': 'OG008'}, {'value': '2.9', 'spread': '16.5', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.4', 'ciLowerLimit': '-2.5', 'ciUpperLimit': '3.3', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.5', 'ciLowerLimit': '-12.5', 'ciUpperLimit': '3.4', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.3', 'ciLowerLimit': '-2.5', 'ciUpperLimit': '1.8', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.5', 'ciLowerLimit': '-4.9', 'ciUpperLimit': '-0.1', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.7', 'ciLowerLimit': '-2.6', 'ciUpperLimit': '1.1', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.9', 'ciLowerLimit': '-4.2', 'ciUpperLimit': '0.3', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.8', 'ciLowerLimit': '-4.0', 'ciUpperLimit': '0.3', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.6', 'ciLowerLimit': '-0.6', 'ciUpperLimit': '5.8', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '3 years', 'description': '\\- Change in the MSIS-29 physical subscale (change from baseline; mean value) The Multiple Sclerosis Impact Scale (MSIS-29) physical subscale measures patient-reported physical impact of multiple sclerosis.\n\nScale range: Minimum score: 1 (least impact). Maximum score: 5 (highest impact). Lower scores indicate better outcomes. Higher scores indicate worse outcomes.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'PRIMARY', 'title': 'Disease-related Impact on Daily Life, Psychological', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-8.5', 'spread': '21.3', 'groupId': 'OG000'}, {'value': '-5.1', 'spread': '20.7', 'groupId': 'OG001'}, {'value': '-23.1', 'spread': '23.8', 'groupId': 'OG002'}, {'value': '-6.8', 'spread': '20.7', 'groupId': 'OG003'}, {'value': '-12.2', 'spread': '22.3', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-3.7', 'spread': '19.5', 'groupId': 'OG005'}, {'value': '-1.7', 'spread': '19.3', 'groupId': 'OG006'}, {'value': '-6.1', 'spread': '20.5', 'groupId': 'OG007'}, {'value': '-4.7', 'spread': '19.5', 'groupId': 'OG008'}, {'value': '-0.3', 'spread': '21.8', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.3', 'ciLowerLimit': '-2.2', 'ciUpperLimit': '6.8', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-8.3', 'ciLowerLimit': '-20.3', 'ciUpperLimit': '3.7', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.4', 'ciLowerLimit': '-2.6', 'ciUpperLimit': '3.5', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.4', 'ciLowerLimit': '-5.8', 'ciUpperLimit': '0.9', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.1', 'ciLowerLimit': '-2.9', 'ciUpperLimit': '2.7', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.5', 'ciLowerLimit': '-4.5', 'ciUpperLimit': '1.6', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.6', 'ciLowerLimit': '-4.7', 'ciUpperLimit': '1.5', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.3', 'ciLowerLimit': '-1.7', 'ciUpperLimit': '6.4', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '3 years', 'description': '\\- Change in the MSIS-29 psychological subscale (change from baseline; mean value) The Multiple Sclerosis Impact Scale (MSIS-29) psychological subscale measures patient-reported psychological impact of multiple sclerosis.\n\nScale range: Minimum score: 1 (least impact). Maximum score: 5 (highest impact). Lower scores indicate better outcomes. Higher scores indicate worse outcomes.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Annualized Relapse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.31', 'groupId': 'OG000'}, {'value': '0.59', 'spread': '0.94', 'groupId': 'OG001'}, {'value': '0.47', 'spread': '0.73', 'groupId': 'OG002'}, {'value': '0.26', 'spread': '0.53', 'groupId': 'OG003'}, {'value': '0.26', 'spread': '0.63', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '0.09', 'spread': '0.34', 'groupId': 'OG005'}, {'value': '0.22', 'spread': '0.54', 'groupId': 'OG006'}, {'value': '0.30', 'spread': '0.67', 'groupId': 'OG007'}, {'value': '0.30', 'spread': '0.72', 'groupId': 'OG008'}, {'value': '0.25', 'spread': '0.61', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.39', 'ciLowerLimit': '0.30', 'ciUpperLimit': '0.48', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.27', 'ciLowerLimit': '0.11', 'ciUpperLimit': '0.42', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.17', 'ciLowerLimit': '0.10', 'ciUpperLimit': '0.23', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.05', 'ciLowerLimit': '-0.03', 'ciUpperLimit': '0.13', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.14', 'ciLowerLimit': '0.08', 'ciUpperLimit': '0.19', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.09', 'ciLowerLimit': '0.01', 'ciUpperLimit': '0.16', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.14', 'ciLowerLimit': '0.06', 'ciUpperLimit': '0.21', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.23', 'ciLowerLimit': '0.13', 'ciUpperLimit': '0.33', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '3 years', 'description': '\\- Comparison of mean number of relapses per year between the different treatments', 'unitOfMeasure': 'percentage of relapses', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Remaining on Drug', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '527', 'groupId': 'OG000'}, {'value': '300', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '191', 'groupId': 'OG003'}, {'value': '167', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '662', 'groupId': 'OG005'}, {'value': '307', 'groupId': 'OG006'}, {'value': '299', 'groupId': 'OG007'}, {'value': '260', 'groupId': 'OG008'}, {'value': '76', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-71.6', 'ciLowerLimit': '-76.6', 'ciUpperLimit': '-66.6', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-66.3', 'ciLowerLimit': '-76.3', 'ciUpperLimit': '-56.4', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-47.3', 'ciLowerLimit': '-53.0', 'ciUpperLimit': '-41.7', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-43.1', 'ciLowerLimit': '-49.6', 'ciUpperLimit': '-36.6', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-41.3', 'ciLowerLimit': '-46.4', 'ciUpperLimit': '-36.2', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.9', 'ciLowerLimit': '-39.8', 'ciUpperLimit': '-28.0', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.9', 'ciLowerLimit': '-39.7', 'ciUpperLimit': '-28.0', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-49.8', 'ciLowerLimit': '-58.0', 'ciUpperLimit': '-41.6', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '3 years', 'description': '\\- Proportion remaining on the index DMT after 3 years', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Increase in EDSS', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.2', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '1.2', 'groupId': 'OG001'}, {'value': '0.2', 'spread': '1.2', 'groupId': 'OG002'}, {'value': '-0.2', 'spread': '1.1', 'groupId': 'OG003'}, {'value': '-0.4', 'spread': '1.2', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.0', 'spread': '0.9', 'groupId': 'OG005'}, {'value': '0.1', 'spread': '0.9', 'groupId': 'OG006'}, {'value': '-0.1', 'spread': '1.1', 'groupId': 'OG007'}, {'value': '0.1', 'spread': '1.0', 'groupId': 'OG008'}, {'value': '0.3', 'spread': '0.9', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.1', 'ciLowerLimit': '-0.1', 'ciUpperLimit': '0.3', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.1', 'ciLowerLimit': '-0.3', 'ciUpperLimit': '0.4', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.1', 'ciLowerLimit': '-0.2', 'ciUpperLimit': '0.1', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.1', 'ciLowerLimit': '-0.3', 'ciUpperLimit': '0.1', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.0', 'ciLowerLimit': '-0.1', 'ciUpperLimit': '0.1', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.1', 'ciLowerLimit': '-0.2', 'ciUpperLimit': '0.1', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.0', 'ciLowerLimit': '-0.1', 'ciUpperLimit': '0.2', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.1', 'ciLowerLimit': '-0.1', 'ciUpperLimit': '0.3', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '3 years', 'description': '\\- Comparison of yearly increase in mean EDSS between the different treatments\n\nExpanded Disability Status Scale (EDSS) scale range:\n\nMinimum score: 0 (normal neurological examination). Maximum score: 10 (death due to multiple sclerosis) Lower scores indicate better outcomes (less disability). Higher scores indicate worse outcomes (more disability).', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Proportion of Patients With at Least 1 Step Increase in EDSS', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '108', 'groupId': 'OG000'}, {'value': '272', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '83', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '135', 'groupId': 'OG005'}, {'value': '114', 'groupId': 'OG006'}, {'value': '117', 'groupId': 'OG007'}, {'value': '93', 'groupId': 'OG008'}, {'value': '39', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.8', 'ciLowerLimit': '-2.2', 'ciUpperLimit': '11.9', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.0', 'ciLowerLimit': '-2.6', 'ciUpperLimit': '20.6', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.7', 'ciLowerLimit': '-7.6', 'ciUpperLimit': '6.2', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.6', 'ciLowerLimit': '-9.4', 'ciUpperLimit': '4.1', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.6', 'ciLowerLimit': '-8.6', 'ciUpperLimit': '3.4', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.8', 'ciLowerLimit': '-4.7', 'ciUpperLimit': '12.2', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.6', 'ciLowerLimit': '-6.9', 'ciUpperLimit': '8.1', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.9', 'ciLowerLimit': '-6.3', 'ciUpperLimit': '14.1', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '3 years', 'description': '\\- Comparison of yearly proportion of patients with at least 1 step increase in EDSS between the different treatments\n\nExpanded Disability Status Scale (EDSS) scale range:\n\nMinimum score: 0 (normal neurological examination). Maximum score: 10 (death due to multiple sclerosis) Lower scores indicate better outcomes (less disability). Higher scores indicate worse outcomes (more disability).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Proportion of Patients With No Evidence of Disease Activity (NEDA) -2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '483', 'groupId': 'OG000'}, {'value': '348', 'groupId': 'OG001'}, {'value': '44', 'groupId': 'OG002'}, {'value': '235', 'groupId': 'OG003'}, {'value': '208', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '638', 'groupId': 'OG005'}, {'value': '356', 'groupId': 'OG006'}, {'value': '326', 'groupId': 'OG007'}, {'value': '226', 'groupId': 'OG008'}, {'value': '95', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-34.1', 'ciLowerLimit': '-40.3', 'ciUpperLimit': '-27.9', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.2', 'ciLowerLimit': '-43.0', 'ciUpperLimit': '-21.5', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-21.8', 'ciLowerLimit': '-27.9', 'ciUpperLimit': '-15.7', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-7.8', 'ciLowerLimit': '-14.5', 'ciUpperLimit': '-1.2', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-23.6', 'ciLowerLimit': '-28.9', 'ciUpperLimit': '-18.3', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-12.7', 'ciLowerLimit': '-18.9', 'ciUpperLimit': '-6.5', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-26.5', 'ciLowerLimit': '-32.8', 'ciUpperLimit': '-20.2', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-31.7', 'ciLowerLimit': '-40.1', 'ciUpperLimit': '-23.2', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '3 years', 'description': '\\- Comparison of yearly proportion of patients with No Evidence of Disease Activity (NEDA) -2 (free of exacerbations, new/enlarged T2-lesions and occurrence of CEL) between the treatments.\n\nLower NEDA-2 scores indicate better outcomes. Higher NEDA-2 scores indicate worse outcomes.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Proportion of Patients With NEDA-3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '467', 'groupId': 'OG000'}, {'value': '340', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '232', 'groupId': 'OG003'}, {'value': '204', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '619', 'groupId': 'OG005'}, {'value': '339', 'groupId': 'OG006'}, {'value': '314', 'groupId': 'OG007'}, {'value': '220', 'groupId': 'OG008'}, {'value': '94', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.2', 'ciLowerLimit': '-39.4', 'ciUpperLimit': '-27.0', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-30.6', 'ciLowerLimit': '-41.4', 'ciUpperLimit': '-19.8', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-20.8', 'ciLowerLimit': '-27.0', 'ciUpperLimit': '-14.7', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-7.0', 'ciLowerLimit': '-13.6', 'ciUpperLimit': '-0.3', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-23.7', 'ciLowerLimit': '-29.2', 'ciUpperLimit': '-18.3', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-12.3', 'ciLowerLimit': '-18.6', 'ciUpperLimit': '-6.1', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-25.3', 'ciLowerLimit': '-31.7', 'ciUpperLimit': '-19.0', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Difference in proportion', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-29.5', 'ciLowerLimit': '-38.2', 'ciUpperLimit': '-20.8', 'groupDescription': 'Data shown are adjusted difference in proportion, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '3 years', 'description': '\\- Comparison of yearly proportion of patients with NEDA-3 (NEDA-2 plus no confirmed worsening of EDSS from baseline).\n\nLower NEDA-3 scores indicate better outcomes. Higher NEDA-3 scores indicate worse outcomes.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Quality of Life Assessments', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '0.77', 'spread': '0.24', 'groupId': 'OG000'}, {'value': '0.77', 'spread': '0.24', 'groupId': 'OG001'}, {'value': '0.74', 'spread': '0.26', 'groupId': 'OG002'}, {'value': '0.81', 'spread': '0.22', 'groupId': 'OG003'}, {'value': '0.76', 'spread': '0.26', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '0.76', 'spread': '0.24', 'groupId': 'OG005'}, {'value': '0.81', 'spread': '0.22', 'groupId': 'OG006'}, {'value': '0.74', 'spread': '0.27', 'groupId': 'OG007'}, {'value': '0.79', 'spread': '0.22', 'groupId': 'OG008'}, {'value': '0.76', 'spread': '0.24', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.03', 'ciLowerLimit': '-0.07', 'ciUpperLimit': '0.00', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.02', 'ciLowerLimit': '-0.09', 'ciUpperLimit': '0.06', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.00', 'ciLowerLimit': '-0.03', 'ciUpperLimit': '0.03', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.01', 'ciLowerLimit': '-0.03', 'ciUpperLimit': '0.05', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.01', 'ciLowerLimit': '-0.02', 'ciUpperLimit': '0.04', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.03', 'ciLowerLimit': '-0.01', 'ciUpperLimit': '0.06', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.03', 'ciLowerLimit': '0.00', 'ciUpperLimit': '0.06', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.02', 'ciLowerLimit': '-0.06', 'ciUpperLimit': '0.03', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '3 years', 'description': 'Comparison of health-related quality of life measured by the European Quality of Life Five Dimensions (EQ-5D). Higher values indicate better health, and lower values indicate poorer health. The maximum theoretical value is 1. While there is no fixed minimum, scores can fall below 0, indicating health states worse than death. In this study, scores ranged from -0.59 to 1, which represent clinically relevant ranges of values.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Fatigue', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '55.1', 'spread': '22.9', 'groupId': 'OG000'}, {'value': '52.1', 'spread': '23.0', 'groupId': 'OG001'}, {'value': '55.7', 'spread': '22.2', 'groupId': 'OG002'}, {'value': '48.3', 'spread': '23.0', 'groupId': 'OG003'}, {'value': '53.2', 'spread': '23.2', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '53.5', 'spread': '23.0', 'groupId': 'OG005'}, {'value': '49.7', 'spread': '21.6', 'groupId': 'OG006'}, {'value': '55.9', 'spread': '23.0', 'groupId': 'OG007'}, {'value': '49.3', 'spread': '22.8', 'groupId': 'OG008'}, {'value': '53.1', 'spread': '22.7', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.9', 'ciLowerLimit': '-3.3', 'ciUpperLimit': '5.2', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.5', 'ciLowerLimit': '-9.4', 'ciUpperLimit': '6.4', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.4', 'ciLowerLimit': '-4.2', 'ciUpperLimit': '1.4', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.6', 'ciLowerLimit': '-5.9', 'ciUpperLimit': '0.8', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.2', 'ciLowerLimit': '-2.9', 'ciUpperLimit': '2.5', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.1', 'ciLowerLimit': '-4.0', 'ciUpperLimit': '1.8', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.1', 'ciLowerLimit': '-7.0', 'ciUpperLimit': '0.9', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.3', 'ciLowerLimit': '-2.9', 'ciUpperLimit': '5.4', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '3 years', 'description': 'Comparison of fatigue measured by the Fatigue Scale for Motor and Cognitive Functions (FSMC).\n\nThe fatigue scale for motor and cognitive functions (FSMC) scale range: Minimum score: 20. Maximum score: 100. Lower scores indicate better outcomes. Higher scores indicate worse outcomes.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Treatment Satisfaction', 'denoms': [{'units': 'Participants', 'counts': [{'value': '544', 'groupId': 'OG000'}, {'value': '282', 'groupId': 'OG001'}, {'value': '36', 'groupId': 'OG002'}, {'value': '191', 'groupId': 'OG003'}, {'value': '168', 'groupId': 'OG004'}, {'value': '692', 'groupId': 'OG005'}, {'value': '309', 'groupId': 'OG006'}, {'value': '303', 'groupId': 'OG007'}, {'value': '263', 'groupId': 'OG008'}, {'value': '77', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '544', 'groupId': 'OG000'}, {'value': '282', 'groupId': 'OG001'}, {'value': '36', 'groupId': 'OG002'}, {'value': '191', 'groupId': 'OG003'}, {'value': '168', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '50.1', 'spread': '6.8', 'groupId': 'OG000'}, {'value': '44.3', 'spread': '7.7', 'groupId': 'OG001'}, {'value': '42.8', 'spread': '8.3', 'groupId': 'OG002'}, {'value': '48.3', 'spread': '7.1', 'groupId': 'OG003'}, {'value': '49.5', 'spread': '6.7', 'groupId': 'OG004'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '692', 'groupId': 'OG005'}, {'value': '309', 'groupId': 'OG006'}, {'value': '303', 'groupId': 'OG007'}, {'value': '263', 'groupId': 'OG008'}, {'value': '77', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '49.5', 'spread': '7.2', 'groupId': 'OG005'}, {'value': '49.0', 'spread': '6.7', 'groupId': 'OG006'}, {'value': '49.5', 'spread': '6.7', 'groupId': 'OG007'}, {'value': '51.8', 'spread': '6.3', 'groupId': 'OG008'}, {'value': '51.6', 'spread': '6.3', 'groupId': 'OG009'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-5.5', 'ciLowerLimit': '-8.1', 'ciUpperLimit': '-2.9', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-5.9', 'ciLowerLimit': '-10.9', 'ciUpperLimit': '-1.0', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.4', 'ciLowerLimit': '-4.0', 'ciUpperLimit': '-0.8', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.3', 'ciLowerLimit': '-2.1', 'ciUpperLimit': '1.5', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG006'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.8', 'ciLowerLimit': '-2.2', 'ciUpperLimit': '0.6', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.3', 'ciLowerLimit': '-0.3', 'ciUpperLimit': '2.8', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.7', 'ciLowerLimit': '0.9', 'ciUpperLimit': '4.6', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG005', 'OG009'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.1', 'ciLowerLimit': '0.2', 'ciUpperLimit': '4.0', 'groupDescription': 'Data shown are adjusted mean differences, stratified by DMT line with rituximab as reference, from multivariable linear regression adjusted for age, sex, year of treatment start, country of birth, geographical region, education level, duration since MS diagnosis, baseline EDSS and MSIS-29 scores, history of serious infection, malignancy, major adverse cardiovascular event, arrhythmia, use of antidepressants, diabetes. Confidence intervals are based on robust (Huber-White) standard errors.', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '3 years', 'description': 'Comparison of patient satisfaction with their treatment using the Treatment Satisfaction Questionnaire (TSQ), items 1-9, restricted to patients remaining on index DMT at 3 years.\n\nThe Treatment Satisfaction Questionnaire (TSQ), items 1-9 scale range: Minimum score: 0. Maximum score: 100. Lower scores indicate worse outcomes. Higher scores indicate better outcomes.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Rate of Serious Infections', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '12.7', 'groupId': 'OG000', 'lowerLimit': '7.9', 'upperLimit': '19.2'}, {'value': '6.8', 'groupId': 'OG001', 'lowerLimit': '4.2', 'upperLimit': '10.5'}, {'value': '5.8', 'groupId': 'OG002', 'lowerLimit': '0.7', 'upperLimit': '21.1'}, {'value': '9.8', 'groupId': 'OG003', 'lowerLimit': '5.0', 'upperLimit': '17.1'}, {'value': '12.2', 'groupId': 'OG004', 'lowerLimit': '6.3', 'upperLimit': '21.2'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '20.2', 'groupId': 'OG005', 'lowerLimit': '14.7', 'upperLimit': '27.2'}, {'value': '5.9', 'groupId': 'OG006', 'lowerLimit': '2.8', 'upperLimit': '10.9'}, {'value': '6.2', 'groupId': 'OG007', 'lowerLimit': '3.0', 'upperLimit': '11.5'}, {'value': '10.7', 'groupId': 'OG008', 'lowerLimit': '5.9', 'upperLimit': '18.0'}, {'value': '14.9', 'groupId': 'OG009', 'lowerLimit': '6.0', 'upperLimit': '30.6'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '3 years', 'description': '\\- Rate of serious infections, defined as hospitalizations where the main diagnosis included an ICD-10 diagnosis code in the national patient register in the 3 years after initiating index DMT', 'unitOfMeasure': 'infections per 1000 person-years', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Rate of Major Adverse Cardiovascular Events (MACE)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.4', 'upperLimit': '5.0'}, {'value': '1.4', 'groupId': 'OG001', 'lowerLimit': '0.4', 'upperLimit': '3.5'}, {'value': '0.0', 'groupId': 'OG002', 'lowerLimit': '0.0', 'upperLimit': '10.6'}, {'value': '0.8', 'groupId': 'OG003', 'lowerLimit': '0.0', 'upperLimit': '4.5'}, {'value': '0.0', 'groupId': 'OG004', 'lowerLimit': '0.0', 'upperLimit': '3.7'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '1.3', 'groupId': 'OG005', 'lowerLimit': '0.3', 'upperLimit': '3.9'}, {'value': '0.6', 'groupId': 'OG006', 'lowerLimit': '0.0', 'upperLimit': '3.3'}, {'value': '1.2', 'groupId': 'OG007', 'lowerLimit': '0.1', 'upperLimit': '4.5'}, {'value': '0.0', 'groupId': 'OG008', 'lowerLimit': '0.0', 'upperLimit': '2.8'}, {'value': '4.2', 'groupId': 'OG009', 'lowerLimit': '0.5', 'upperLimit': '15.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '3 years', 'description': '\\- Rate of MACE, defined as acute coronary syndrome, stroke or death from any cardiovascular cause based on corresponding ICD-codes in the national patient and cause of death registries in the 3 years after initiating index DMT', 'unitOfMeasure': 'MACE per 1000 person-years', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}, {'type': 'SECONDARY', 'title': 'Rate of Invasive Cancer', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'OG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'OG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'OG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'OG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'OG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'OG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'OG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'OG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'OG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'OG000'}, {'value': '992', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}, {'value': '416', 'groupId': 'OG003'}, {'value': '334', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '0.6', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.2'}, {'value': '2.4', 'groupId': 'OG001', 'lowerLimit': '1.0', 'upperLimit': '4.9'}, {'value': '2.9', 'groupId': 'OG002', 'lowerLimit': '0.1', 'upperLimit': '16.2'}, {'value': '0.0', 'groupId': 'OG003', 'lowerLimit': '0.0', 'upperLimit': '3.0'}, {'value': '3.0', 'groupId': 'OG004', 'lowerLimit': '0.6', 'upperLimit': '8.8'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '748', 'groupId': 'OG005'}, {'value': '570', 'groupId': 'OG006'}, {'value': '541', 'groupId': 'OG007'}, {'value': '443', 'groupId': 'OG008'}, {'value': '161', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '1.3', 'groupId': 'OG005', 'lowerLimit': '0.3', 'upperLimit': '3.9'}, {'value': '3.0', 'groupId': 'OG006', 'lowerLimit': '1.0', 'upperLimit': '6.9'}, {'value': '1.2', 'groupId': 'OG007', 'lowerLimit': '0.1', 'upperLimit': '4.5'}, {'value': '4.6', 'groupId': 'OG008', 'lowerLimit': '1.7', 'upperLimit': '9.9'}, {'value': '0.0', 'groupId': 'OG009', 'lowerLimit': '0.0', 'upperLimit': '7.7'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '3 years', 'description': '\\- Rate of incident invasive cancer, defined as invasive cancers based on corresponding ICD-codes in the national cancer registry in the 3 years after initiating index DMT.', 'unitOfMeasure': 'invasive cancer per 1000 person-years', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'First line and Second line reported in separate rows'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'FG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'FG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'FG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'FG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'FG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'FG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'FG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'FG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'FG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}], 'periods': [{'title': 'First Line', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numUnits': '591', 'numSubjects': '591'}, {'groupId': 'FG001', 'numUnits': '992', 'numSubjects': '992'}, {'groupId': 'FG002', 'numUnits': '116', 'numSubjects': '116'}, {'groupId': 'FG003', 'numUnits': '416', 'numSubjects': '416'}, {'groupId': 'FG004', 'numUnits': '334', 'numSubjects': '334'}, {'groupId': 'FG005', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG006', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG007', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG008', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG009', 'numUnits': '0', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numUnits': '591', 'numSubjects': '591'}, {'groupId': 'FG001', 'numUnits': '992', 'numSubjects': '992'}, {'groupId': 'FG002', 'numUnits': '116', 'numSubjects': '116'}, {'groupId': 'FG003', 'numUnits': '416', 'numSubjects': '416'}, {'groupId': 'FG004', 'numUnits': '334', 'numSubjects': '334'}, {'groupId': 'FG005', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG006', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG007', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG008', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG009', 'numUnits': '0', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG001', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG002', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG003', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG004', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG005', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG006', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG007', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG008', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG009', 'numUnits': '0', 'numSubjects': '0'}]}]}, {'title': 'Second Line', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG001', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG002', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG003', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG004', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG005', 'numUnits': '748', 'numSubjects': '748'}, {'groupId': 'FG006', 'numUnits': '570', 'numSubjects': '570'}, {'groupId': 'FG007', 'numUnits': '541', 'numSubjects': '541'}, {'groupId': 'FG008', 'numUnits': '443', 'numSubjects': '443'}, {'groupId': 'FG009', 'numUnits': '161', 'numSubjects': '161'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG001', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG002', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG003', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG004', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG005', 'numUnits': '748', 'numSubjects': '748'}, {'groupId': 'FG006', 'numUnits': '570', 'numSubjects': '570'}, {'groupId': 'FG007', 'numUnits': '541', 'numSubjects': '541'}, {'groupId': 'FG008', 'numUnits': '443', 'numSubjects': '443'}, {'groupId': 'FG009', 'numUnits': '161', 'numSubjects': '161'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG001', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG002', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG003', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG004', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG005', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG006', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG007', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG008', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG009', 'numUnits': '0', 'numSubjects': '0'}]}]}], 'typeUnitsAnalyzed': 'Treatment Episodes', 'recruitmentDetails': "Note that unique patients could contribute to more than one treatment group, both with their first line and second line DMT, or exclusively in the first line or second line DMT group, as based on baseline characteristics. The 'total' automatically summed across groups should be interpreted as the total number of participants in first line DMT and second line DMT, respectively."}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '3764', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'groups': [{'id': 'BG000', 'title': 'RTX (First Line)', 'description': 'Rituximab (First line)'}, {'id': 'BG001', 'title': 'IFN (First Line)', 'description': 'Interferons, first line DMT'}, {'id': 'BG002', 'title': 'GA (First Line)', 'description': 'Glatiramer acetate, first line DMT'}, {'id': 'BG003', 'title': 'DMF (First Line)', 'description': 'Dimethyl fumarate, first line DMT'}, {'id': 'BG004', 'title': 'NTZ (First Line)', 'description': 'Natalizumab, first line DMT'}, {'id': 'BG005', 'title': 'RTX (Second Line)', 'description': 'Rituximab, as first second line DMT'}, {'id': 'BG006', 'title': 'DMF (Second Line)', 'description': 'Dimethyl fumarate, as first second line DMT'}, {'id': 'BG007', 'title': 'NTZ (Second Line)', 'description': 'Natalizumab, as first second line DMT'}, {'id': 'BG008', 'title': 'FGL (Second Line)', 'description': 'Fingolimod, as first second line DMT'}, {'id': 'BG009', 'title': 'TFL (Second Line)', 'description': 'Teriflunomide, as first second line DMT'}, {'id': 'BG010', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '36.9', 'spread': '11.3', 'groupId': 'BG000'}, {'value': '35.8', 'spread': '10.5', 'groupId': 'BG001'}, {'value': '36.9', 'spread': '11.7', 'groupId': 'BG002'}, {'value': '34.4', 'spread': '9.7', 'groupId': 'BG003'}, {'value': '31.6', 'spread': '9.2', 'groupId': 'BG004'}, {'value': '35.3', 'spread': '10.6', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '39.0', 'spread': '10.5', 'groupId': 'BG005'}, {'value': '40.6', 'spread': '10.6', 'groupId': 'BG006'}, {'value': '35.1', 'spread': '9.6', 'groupId': 'BG007'}, {'value': '37.3', 'spread': '9.4', 'groupId': 'BG008'}, {'value': '46.3', 'spread': '9.8', 'groupId': 'BG009'}, {'value': '38.7', 'spread': '10.5', 'groupId': 'BG010'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Sex: Female, Male', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '399', 'groupId': 'BG000'}, {'value': '705', 'groupId': 'BG001'}, {'value': '90', 'groupId': 'BG002'}, {'value': '283', 'groupId': 'BG003'}, {'value': '242', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '1719', 'groupId': 'BG010'}]}, {'title': 'Male', 'measurements': [{'value': '192', 'groupId': 'BG000'}, {'value': '287', 'groupId': 'BG001'}, {'value': '26', 'groupId': 'BG002'}, {'value': '133', 'groupId': 'BG003'}, {'value': '92', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '730', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '560', 'groupId': 'BG005'}, {'value': '418', 'groupId': 'BG006'}, {'value': '406', 'groupId': 'BG007'}, {'value': '292', 'groupId': 'BG008'}, {'value': '116', 'groupId': 'BG009'}, {'value': '1792', 'groupId': 'BG010'}]}, {'title': 'Male', 'measurements': [{'value': '188', 'groupId': 'BG005'}, {'value': '152', 'groupId': 'BG006'}, {'value': '135', 'groupId': 'BG007'}, {'value': '151', 'groupId': 'BG008'}, {'value': '45', 'groupId': 'BG009'}, {'value': '671', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Race and Ethnicity Not Collected', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'Race and Ethnicity were not collected from any participant.'}, {'title': 'Region of Enrollment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'classes': [{'title': 'Sweden', 'categories': [{'measurements': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '2449', 'groupId': 'BG010'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line reported separately as unique patients could contribute to more than one treatment groups, both with their first line and secoond line DMT'}, {'title': 'Region of Enrollment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'classes': [{'title': 'Sweden', 'categories': [{'measurements': [{'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'Second line reported separately as unique patients could contribute to more than one treatment groups, both with their first line and secoond line DMT'}, {'title': 'Year of DMT start', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '2016', 'groupId': 'BG000', 'lowerLimit': '2015', 'upperLimit': '2017'}, {'value': '2013', 'groupId': 'BG001', 'lowerLimit': '2012', 'upperLimit': '2014'}, {'value': '2013', 'groupId': 'BG002', 'lowerLimit': '2012', 'upperLimit': '2014'}, {'value': '2015', 'groupId': 'BG003', 'lowerLimit': '2014', 'upperLimit': '2017'}, {'value': '2014', 'groupId': 'BG004', 'lowerLimit': '2013', 'upperLimit': '2016'}, {'value': '2014', 'groupId': 'BG010', 'lowerLimit': '2012', 'upperLimit': '2016'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '2016', 'groupId': 'BG005', 'lowerLimit': '2014', 'upperLimit': '2017'}, {'value': '2015', 'groupId': 'BG006', 'lowerLimit': '2014', 'upperLimit': '2016'}, {'value': '2013', 'groupId': 'BG007', 'lowerLimit': '2012', 'upperLimit': '2014'}, {'value': '2013', 'groupId': 'BG008', 'lowerLimit': '2012', 'upperLimit': '2014'}, {'value': '2015', 'groupId': 'BG009', 'lowerLimit': '2015', 'upperLimit': '2017'}, {'value': '2014', 'groupId': 'BG010', 'lowerLimit': '2013', 'upperLimit': '2016'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'year', 'dispersionType': 'INTER_QUARTILE_RANGE', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Born in Sweden', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '494', 'groupId': 'BG000'}, {'value': '782', 'groupId': 'BG001'}, {'value': '98', 'groupId': 'BG002'}, {'value': '337', 'groupId': 'BG003'}, {'value': '278', 'groupId': 'BG004'}, {'value': '1989', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '605', 'groupId': 'BG005'}, {'value': '466', 'groupId': 'BG006'}, {'value': '460', 'groupId': 'BG007'}, {'value': '361', 'groupId': 'BG008'}, {'value': '139', 'groupId': 'BG009'}, {'value': '2031', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Education, 12+ years', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '310', 'groupId': 'BG000'}, {'value': '545', 'groupId': 'BG001'}, {'value': '61', 'groupId': 'BG002'}, {'value': '226', 'groupId': 'BG003'}, {'value': '161', 'groupId': 'BG004'}, {'value': '1303', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '403', 'groupId': 'BG005'}, {'value': '309', 'groupId': 'BG006'}, {'value': '272', 'groupId': 'BG007'}, {'value': '234', 'groupId': 'BG008'}, {'value': '89', 'groupId': 'BG009'}, {'value': '1307', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'n (%) with at least 12 years of education', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Years since MS diagnosis', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '4.0', 'groupId': 'BG000'}, {'value': '0.9', 'spread': '3.1', 'groupId': 'BG001'}, {'value': '1.7', 'spread': '4.5', 'groupId': 'BG002'}, {'value': '0.6', 'spread': '2.3', 'groupId': 'BG003'}, {'value': '0.5', 'spread': '1.9', 'groupId': 'BG004'}, {'value': '0.9', 'spread': '3.2', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '5.6', 'spread': '5.5', 'groupId': 'BG005'}, {'value': '7.1', 'spread': '5.9', 'groupId': 'BG006'}, {'value': '4.7', 'spread': '4.8', 'groupId': 'BG007'}, {'value': '5.6', 'spread': '4.8', 'groupId': 'BG008'}, {'value': '9.3', 'spread': '6.9', 'groupId': 'BG009'}, {'value': '6.0', 'spread': '5.6', 'groupId': 'BG010'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Any relapse last year', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '367', 'groupId': 'BG000'}, {'value': '648', 'groupId': 'BG001'}, {'value': '62', 'groupId': 'BG002'}, {'value': '265', 'groupId': 'BG003'}, {'value': '252', 'groupId': 'BG004'}, {'value': '1594', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '254', 'groupId': 'BG005'}, {'value': '120', 'groupId': 'BG006'}, {'value': '288', 'groupId': 'BG007'}, {'value': '172', 'groupId': 'BG008'}, {'value': '30', 'groupId': 'BG009'}, {'value': '864', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'EDSS', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '2.0', 'spread': '1.3', 'groupId': 'BG000'}, {'value': '1.6', 'spread': '1.2', 'groupId': 'BG001'}, {'value': '1.4', 'spread': '1.2', 'groupId': 'BG002'}, {'value': '1.5', 'spread': '1.1', 'groupId': 'BG003'}, {'value': '2.1', 'spread': '1.3', 'groupId': 'BG004'}, {'value': '1.7', 'spread': '1.2', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '2.0', 'spread': '1.3', 'groupId': 'BG005'}, {'value': '1.6', 'spread': '1.3', 'groupId': 'BG006'}, {'value': '2.2', 'spread': '1.4', 'groupId': 'BG007'}, {'value': '1.8', 'spread': '1.3', 'groupId': 'BG008'}, {'value': '1.8', 'spread': '1.6', 'groupId': 'BG009'}, {'value': '1.9', 'spread': '1.4', 'groupId': 'BG010'}]}]}], 'paramType': 'MEAN', 'description': 'Mean (Standard Deviation) Expanded Disability Status Scale (EDSS)\n\nScale range:\n\nMinimum score: 0 (normal neurological examination) Maximum score: 10 (death due to multiple sclerosis)\n\nLower scores indicate better outcomes (less disability). Higher scores indicate worse outcomes (more disability).', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'STANDARD_DEVIATION', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'MSIS-29 physical', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '0.8', 'groupId': 'BG000'}, {'value': '1.6', 'spread': '0.7', 'groupId': 'BG001'}, {'value': '1.7', 'spread': '0.6', 'groupId': 'BG002'}, {'value': '1.7', 'spread': '0.8', 'groupId': 'BG003'}, {'value': '2.0', 'spread': '0.9', 'groupId': 'BG004'}, {'value': '1.8', 'spread': '0.8', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '1.7', 'spread': '0.8', 'groupId': 'BG005'}, {'value': '1.6', 'spread': '0.7', 'groupId': 'BG006'}, {'value': '1.9', 'spread': '0.9', 'groupId': 'BG007'}, {'value': '1.7', 'spread': '0.8', 'groupId': 'BG008'}, {'value': '1.7', 'spread': '0.7', 'groupId': 'BG009'}, {'value': '1.8', 'spread': '0.8', 'groupId': 'BG010'}]}]}], 'paramType': 'MEAN', 'description': 'Mean (Standard Deviation) Multiple Sclerosis Impact Scale (MSIS-29) physical subscale.\n\nMeasures patient-reported physical impact of multiple sclerosis. Scale range: Minimum score: 1 (least impact). Maximum score: 5 (highest impact). Lower scores indicate better outcomes. Higher scores indicate worse outcomes.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'STANDARD_DEVIATION', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'MSIS-29 psychological', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '2.4', 'spread': '1.0', 'groupId': 'BG000'}, {'value': '2.2', 'spread': '0.9', 'groupId': 'BG001'}, {'value': '2.6', 'spread': '0.9', 'groupId': 'BG002'}, {'value': '2.3', 'spread': '1.0', 'groupId': 'BG003'}, {'value': '2.6', 'spread': '1.0', 'groupId': 'BG004'}, {'value': '2.4', 'spread': '1.0', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '2.2', 'spread': '1.0', 'groupId': 'BG005'}, {'value': '2.0', 'spread': '0.9', 'groupId': 'BG006'}, {'value': '2.4', 'spread': '1.0', 'groupId': 'BG007'}, {'value': '2.2', 'spread': '0.9', 'groupId': 'BG008'}, {'value': '2.1', 'spread': '1.0', 'groupId': 'BG009'}, {'value': '2.2', 'spread': '1.0', 'groupId': 'BG010'}]}]}], 'paramType': 'MEAN', 'description': 'Mean (Standard Deviation) Multiple Sclerosis Impact Scale (MSIS-29) psychological subscale.\n\nMeasures patient-reported psychological impact of multiple sclerosis. Scale range: Minimum score: 1 (least impact). Maximum score: 5 (highest impact). Lower scores indicate better outcomes. Higher scores indicate worse outcomes.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'STANDARD_DEVIATION', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Serious infection', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '15', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '7', 'groupId': 'BG003'}, {'value': '16', 'groupId': 'BG004'}, {'value': '60', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '21', 'groupId': 'BG005'}, {'value': '17', 'groupId': 'BG006'}, {'value': '21', 'groupId': 'BG007'}, {'value': '12', 'groupId': 'BG008'}, {'value': '6', 'groupId': 'BG009'}, {'value': '77', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'n (%) with hospitalization due to infection in the last five years', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Cancer', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '24', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG005'}, {'value': '10', 'groupId': 'BG006'}, {'value': '2', 'groupId': 'BG007'}, {'value': '6', 'groupId': 'BG008'}, {'value': '7', 'groupId': 'BG009'}, {'value': '35', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'n (%) with any diagnosis of invasive cancer in the last five years', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Antidepressant use', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '88', 'groupId': 'BG000'}, {'value': '98', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '64', 'groupId': 'BG003'}, {'value': '35', 'groupId': 'BG004'}, {'value': '310', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '124', 'groupId': 'BG005'}, {'value': '92', 'groupId': 'BG006'}, {'value': '108', 'groupId': 'BG007'}, {'value': '81', 'groupId': 'BG008'}, {'value': '42', 'groupId': 'BG009'}, {'value': '447', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'n (%) with any filled prescription of antidepressant last year.', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'MACE', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '28', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG005'}, {'value': '6', 'groupId': 'BG006'}, {'value': '5', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '4', 'groupId': 'BG009'}, {'value': '22', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'n (%) with any diagnosis major adverse cardiovascular event (MACE) in the last five years', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Arrhythmia', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '21', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '11', 'groupId': 'BG005'}, {'value': '5', 'groupId': 'BG006'}, {'value': '8', 'groupId': 'BG007'}, {'value': '6', 'groupId': 'BG008'}, {'value': '1', 'groupId': 'BG009'}, {'value': '31', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'n (%) with any diagnosis of arrythmia in the last five years', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}, {'title': 'Diabetes', 'classes': [{'title': 'First line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2449', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '7', 'groupId': 'BG004'}, {'value': '43', 'groupId': 'BG010'}]}]}, {'title': 'Second line', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '2463', 'groupId': 'BG010'}]}, {'units': 'Treatment Episodes', 'counts': [{'value': '591', 'groupId': 'BG000'}, {'value': '992', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}, {'value': '416', 'groupId': 'BG003'}, {'value': '334', 'groupId': 'BG004'}, {'value': '748', 'groupId': 'BG005'}, {'value': '570', 'groupId': 'BG006'}, {'value': '541', 'groupId': 'BG007'}, {'value': '443', 'groupId': 'BG008'}, {'value': '161', 'groupId': 'BG009'}, {'value': '4912', 'groupId': 'BG010'}]}], 'categories': [{'measurements': [{'value': '17', 'groupId': 'BG005'}, {'value': '12', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '5', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '42', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'n (%) with any diagnosis of diabetes in the last five years', 'unitOfMeasure': 'Participants', 'denomUnitsSelected': 'Participants', 'populationDescription': 'First line and Second line reported in separate rows'}], 'typeUnitsAnalyzed': 'Treatment Episodes', 'populationDescription': 'Unique patients could conribute to more than one treatment group, both with their first line and second line DMT'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-05-25', 'size': 406442, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2023-09-11T11:03', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Serum samples will be taken yearly for analysis of anti-drug antibodies. These samples will be saved in biobank.\n\nAdditional blood samples will be taken for analyses of SARS-CoV-2 serologic response.'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'OTHER', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 3526}, 'targetDuration': '3 Years', 'patientRegistry': True}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-06-02', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-03', 'completionDateStruct': {'date': '2022-03-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-03-31', 'studyFirstSubmitDate': '2017-04-20', 'resultsFirstSubmitDate': '2023-09-11', 'studyFirstSubmitQcDate': '2017-06-18', 'lastUpdatePostDateStruct': {'date': '2025-04-20', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-03-31', 'studyFirstPostDateStruct': {'date': '2017-06-21', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-04-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-03-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Confirmed Disease Progression in Patients With Expanded Disability Status Scale (EDSS) <2.5 at Baseline', 'timeFrame': '3 years', 'description': 'Proportion of patients with baseline EDSS \\<2.5 progressing to 12 months confirmed EDSS ≥3 among those over 3 years of follow up.\n\nExpanded Disability Status Scale (EDSS) scale range:\n\nMinimum score: 0 (normal neurological examination). Maximum score: 10 (death due to multiple sclerosis) Lower scores indicate better outcomes (less disability). Higher scores indicate worse outcomes (more disability).'}, {'measure': 'Confirmed Disease Progression in Patients With EDSS ≥2.5 at Baseline', 'timeFrame': '3 years', 'description': '\\- Proportion of patients with baseline EDSS ≥2.5 experiencing 12 months confirmed EDSS increase of 1 point among those over 3 years of follow up\n\nExpanded Disability Status Scale (EDSS) scale range:\n\nMinimum score: 0 (normal neurological examination). Maximum score: 10 (death due to multiple sclerosis) Lower scores indicate better outcomes (less disability). Higher scores indicate worse outcomes (more disability).'}, {'measure': 'Disease-related Impact on Daily Life, Physical', 'timeFrame': '3 years', 'description': '\\- Change in the MSIS-29 physical subscale (change from baseline; mean value) The Multiple Sclerosis Impact Scale (MSIS-29) physical subscale measures patient-reported physical impact of multiple sclerosis.\n\nScale range: Minimum score: 1 (least impact). Maximum score: 5 (highest impact). Lower scores indicate better outcomes. Higher scores indicate worse outcomes.'}, {'measure': 'Disease-related Impact on Daily Life, Psychological', 'timeFrame': '3 years', 'description': '\\- Change in the MSIS-29 psychological subscale (change from baseline; mean value) The Multiple Sclerosis Impact Scale (MSIS-29) psychological subscale measures patient-reported psychological impact of multiple sclerosis.\n\nScale range: Minimum score: 1 (least impact). Maximum score: 5 (highest impact). Lower scores indicate better outcomes. Higher scores indicate worse outcomes.'}], 'secondaryOutcomes': [{'measure': 'Annualized Relapse Rate', 'timeFrame': '3 years', 'description': '\\- Comparison of mean number of relapses per year between the different treatments'}, {'measure': 'Remaining on Drug', 'timeFrame': '3 years', 'description': '\\- Proportion remaining on the index DMT after 3 years'}, {'measure': 'Increase in EDSS', 'timeFrame': '3 years', 'description': '\\- Comparison of yearly increase in mean EDSS between the different treatments\n\nExpanded Disability Status Scale (EDSS) scale range:\n\nMinimum score: 0 (normal neurological examination). Maximum score: 10 (death due to multiple sclerosis) Lower scores indicate better outcomes (less disability). Higher scores indicate worse outcomes (more disability).'}, {'measure': 'Proportion of Patients With at Least 1 Step Increase in EDSS', 'timeFrame': '3 years', 'description': '\\- Comparison of yearly proportion of patients with at least 1 step increase in EDSS between the different treatments\n\nExpanded Disability Status Scale (EDSS) scale range:\n\nMinimum score: 0 (normal neurological examination). Maximum score: 10 (death due to multiple sclerosis) Lower scores indicate better outcomes (less disability). Higher scores indicate worse outcomes (more disability).'}, {'measure': 'Proportion of Patients With No Evidence of Disease Activity (NEDA) -2', 'timeFrame': '3 years', 'description': '\\- Comparison of yearly proportion of patients with No Evidence of Disease Activity (NEDA) -2 (free of exacerbations, new/enlarged T2-lesions and occurrence of CEL) between the treatments.\n\nLower NEDA-2 scores indicate better outcomes. Higher NEDA-2 scores indicate worse outcomes.'}, {'measure': 'Proportion of Patients With NEDA-3', 'timeFrame': '3 years', 'description': '\\- Comparison of yearly proportion of patients with NEDA-3 (NEDA-2 plus no confirmed worsening of EDSS from baseline).\n\nLower NEDA-3 scores indicate better outcomes. Higher NEDA-3 scores indicate worse outcomes.'}, {'measure': 'Quality of Life Assessments', 'timeFrame': '3 years', 'description': 'Comparison of health-related quality of life measured by the European Quality of Life Five Dimensions (EQ-5D). Higher values indicate better health, and lower values indicate poorer health. The maximum theoretical value is 1. While there is no fixed minimum, scores can fall below 0, indicating health states worse than death. In this study, scores ranged from -0.59 to 1, which represent clinically relevant ranges of values.'}, {'measure': 'Fatigue', 'timeFrame': '3 years', 'description': 'Comparison of fatigue measured by the Fatigue Scale for Motor and Cognitive Functions (FSMC).\n\nThe fatigue scale for motor and cognitive functions (FSMC) scale range: Minimum score: 20. Maximum score: 100. Lower scores indicate better outcomes. Higher scores indicate worse outcomes.'}, {'measure': 'Treatment Satisfaction', 'timeFrame': '3 years', 'description': 'Comparison of patient satisfaction with their treatment using the Treatment Satisfaction Questionnaire (TSQ), items 1-9, restricted to patients remaining on index DMT at 3 years.\n\nThe Treatment Satisfaction Questionnaire (TSQ), items 1-9 scale range: Minimum score: 0. Maximum score: 100. Lower scores indicate worse outcomes. Higher scores indicate better outcomes.'}, {'measure': 'Rate of Serious Infections', 'timeFrame': '3 years', 'description': '\\- Rate of serious infections, defined as hospitalizations where the main diagnosis included an ICD-10 diagnosis code in the national patient register in the 3 years after initiating index DMT'}, {'measure': 'Rate of Major Adverse Cardiovascular Events (MACE)', 'timeFrame': '3 years', 'description': '\\- Rate of MACE, defined as acute coronary syndrome, stroke or death from any cardiovascular cause based on corresponding ICD-codes in the national patient and cause of death registries in the 3 years after initiating index DMT'}, {'measure': 'Rate of Invasive Cancer', 'timeFrame': '3 years', 'description': '\\- Rate of incident invasive cancer, defined as invasive cancers based on corresponding ICD-codes in the national cancer registry in the 3 years after initiating index DMT.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Immunomodulating treatment', 'Cohort study', 'Dimethyl fumarate', 'Fingolimod', 'Interferon-beta', 'Natalizumab', 'Rituximab', 'Glatiramer acetate'], 'conditions': ['Relapsing-remitting Multiple Sclerosis']}, 'descriptionModule': {'briefSummary': 'The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the largest real-world population-based structured prospective follow-up cohort of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. The study will include both treatment naïve patients starting their first DMT and patients switching from a previous first line DMT (escalation/second-line).', 'detailedDescription': 'This is a prospective non-intervention observational prospective cohort study assessing the long-term safety and efficacy of RTX treatment in MS compared with other common MS DMTs regarding both clinical and radiological parameters in a real-life population of patients with MS.\n\nA number of parameters will be assessed annually. These include baseline demographics, previous drug history and reasons for discontinuation, disability status (expanded disability status scale), relapses, safety and adverse events (AE), contrast enhancing T1 and newly appearing T2 lesions on magnetic resonance imaging, as well as a panel of patient reported outcome measures: Symbol Digit Modalities Test (SDMT); MS impact scale-29 (MSIS-29) Fatigue Scale for Motor and Cognitive Functions (FSMC), EuroQol-5 Dimensions (EQ-5D), the MS check scale and Treatment Satisfaction Questionnaire 9 (TSQM-9).\n\nRetrospective data entered in medical charts and the Swedish MS registry will be included together with prospective annual structured follow up from inclusion into the study for a minimum of three years (three to nine years).\n\nIn a substudy - Covid Enhancement study - analyses will be performed regarding the effect of COVID-19 on people with MS as compared to non-MS individuals and also if there is any indication that a particular DMD is associated with a risk to contract a more severe COVID-19. The analyses will primarily be performed in official health care databases.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'All patients initiated at their first or second disease-modifying drug between January 1 2011 and June 30 2018 will be included in the trial. Up to present date, study-related data will be retrospectively controlled via individual study of patient records. Patients will be identified through the Swedish MS registry. Inclusion into the COMBAT-MS core study will be subject to written informed consent. Given the non-intervention design of the study and very limited study-specific procedures outside of clinical practise, we expect participation rates to be very high. Based on preliminary calculations from the MS registry the projected number of participants will be 3700 patients, out of which at least 1000 are treated with rituximab first or second-line.', 'healthyVolunteers': False, 'eligibilityCriteria': 'INCLUSION CRITERIA:\n\nThe study population consists of all patients with Clinically Isolated Syndrome (CIS) or RRMS who;\n\n* Initiate a first MS DMT (treatment naïve), or Initiate a second ever DMT, of a different drug class than the first, regardless of time between drugs or reason for discontinuation("switchers") from 1st Jan 2011 to 30st June 2018, and\n* Are followed at any of the University clinics of Sweden, and\n* Consent to participation in COMBAT-MS core, and\n* Are expected to be capable to follow study assessments.\n\nEXCLUSION CRITERIA:\n\n\\- Patients with progressive forms of MS at start of therapy are not eligible'}, 'identificationModule': {'nctId': 'NCT03193866', 'acronym': 'COMBAT-MS', 'briefTitle': 'COMparison Between All immunoTherapies for Multiple Sclerosis.', 'organization': {'class': 'OTHER', 'fullName': 'Karolinska Institutet'}, 'officialTitle': "COMparison Between All immunoTherapies for Multiple Sclerosis. An Observational Long-term Prospective Cohort Study of Safety, Efficacy and Patient's Satisfaction of MS Disease Modulatory Treatments in Relapsing-remitting Multiple Sclerosis", 'orgStudyIdInfo': {'id': 'COMBAT-MS'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Rituximab', 'type': 'DRUG', 'otherNames': ['Natalizumab', 'Fingolimod', 'Alemtuzumab', 'Interferon-beta', 'Glatiramer acetate', 'Dimethyl Fumarate'], 'description': 'Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis'}]}, 'contactsLocationsModule': {'locations': [{'city': 'Stockholm', 'country': 'Sweden', 'facility': 'Fredrik Piehl', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}], 'overallOfficials': [{'name': 'Fredrik Piehl, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Karolinska Institutet'}, {'name': 'Anders Svenningsson, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Karolinska Institutet'}, {'name': 'Anna Fogdell-Hahn, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Karolinska Institutet'}, {'name': 'Ingrid Kockum, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Karolinska Institutet'}, {'name': 'Thomas Frisell, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Karolinska Institutet'}, {'name': 'Annette Langer-Gould, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Kaiser Permanent Southern California, Los Angeles, USA'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Karolinska Institutet', 'class': 'OTHER'}, 'collaborators': [{'name': 'Patient-Centered Outcomes Research Institute', 'class': 'OTHER'}, {'name': 'Kaiser Foundation Research Institute', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Fredrik Piehl', 'investigatorAffiliation': 'Karolinska Institutet'}}}}